StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Citi Reiterates Buy Rating on Novartis (NVS)
October 15, 2019 3:41 AM
Citi analyst Andrew Baum reiterated a Buy rating and CHF99.00 price target on Novartis (NOVN:SW) (NYSE: NVS).The analyst comments "Despite ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Intl Ratings
Next Articles
AstraZeneca (AZN) Reports Trastuzumab Deruxtecan Granted FDA Priority Review for Treatment of Patients with HER2-Positive Metastatic Breast Cancer
October 17, 2019 7:01 AM